Selected research
Industry Growth & Trends
Global Biosimilar Therapeutic Peptides Industry Growth and Trends Forecast to 2032
Market perspective
According to APO Research, the global Biosimilar Therapeutic Peptides market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The North America market for Biosimilar Therapeutic Peptides is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.
The Europe market for Biosimilar Therapeutic Peptides is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Biosimilar Therapeutic Peptides is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global companies in the Biosimilar Therapeutic Peptides market include Takeda Pharmaceuticals, Sanofi, Novartis AG, li Lilly and Company, Pfizer, GlaxoSmithKline, Amgen, AstraZeneca and Teva Pharmaceuticals, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report provides a structured, data-driven view of the global Biosimilar Therapeutic Peptides market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.
The Biosimilar Therapeutic Peptides market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Biosimilar Therapeutic Peptides market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Biosimilar Therapeutic Peptides.
Key Companies & Market Share Insights
This section analyzes the strategies and performance of leading companies in the global Biosimilar Therapeutic Peptides market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.
Biosimilar Therapeutic Peptides Market by Company
Takeda Pharmaceuticals
Sanofi
Novartis AG
li Lilly and Company
Pfizer
GlaxoSmithKline
Amgen
AstraZeneca
Teva Pharmaceuticals
Novo Nordisk
Biosimilar Therapeutic Peptides Segment by Type
Innovative
Generic
Biosimilar Therapeutic Peptides Segment by Application
Cancer
Metabolic Disorders
Dermatology
Gastrointestinal Disorders
Cardiovascular
Central Nervous Systems
Others
Biosimilar Therapeutic Peptides Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Biosimilar Therapeutic Peptides market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Biosimilar Therapeutic Peptides and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Biosimilar Therapeutic Peptides.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 5: Detailed analysis of Biosimilar Therapeutic Peptides companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.
Chapter 12: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Innovative
- Generic
Applications
- Cancer
- Metabolic Disorders
- Dermatology
- Gastrointestinal Disorders
- Cardiovascular
- Central Nervous Systems
- Others
Companies covered
- Takeda Pharmaceuticals
- Sanofi
- Novartis AG
- li Lilly and Company
- Pfizer
- GlaxoSmithKline
- Amgen
- AstraZeneca
- Teva Pharmaceuticals
- Novo Nordisk
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.3 Global Biosimilar Therapeutic Peptides Market Size Overview by Region 2021 VS 2025 VS 2032
- 1.4 Global Biosimilar Therapeutic Peptides Market Size by Region (2021-2032)
- 1.4.1 Global Biosimilar Therapeutic Peptides Market Size by Region (2021-2026)
- 1.4.2 Global Biosimilar Therapeutic Peptides Market Size by Region (2027-2032)
- 1.5 Key Regions Biosimilar Therapeutic Peptides Market Size (2021-2032)
- 1.5.1 North America Biosimilar Therapeutic Peptides Market Size Growth Rate (2021-2032)
- 1.5.2 Europe Biosimilar Therapeutic Peptides Market Size Growth Rate (2021-2032)
- 1.5.3 Asia-Pacific Biosimilar Therapeutic Peptides Market Size Growth Rate (2021-2032)
- 1.5.4 South America Biosimilar Therapeutic Peptides Market Size Growth Rate (2021-2032)
- 1.5.5 Middle East & Africa Biosimilar Therapeutic Peptides Market Size Growth Rate (2021-2032)
2 Biosimilar Therapeutic Peptides Market by Type
- 2.1 Type Introduction
- 2.1.1 Innovative
- 2.1.2 Generic
- 2.2 Global Biosimilar Therapeutic Peptides Market Size by Type
- 2.2.1 Global Biosimilar Therapeutic Peptides Market Size Overview by Type (2021-2032)
- 2.2.2 Global Biosimilar Therapeutic Peptides Historic Market Size Review by Type (2021-2026)
- 2.2.3 Global Biosimilar Therapeutic Peptides Market Size Forecasted by Type (2027-2032)
- 2.3 Global Biosimilar Therapeutic Peptides Market Size by Regions
- 2.3.1 North America Biosimilar Therapeutic Peptides Market Size Breakdown by Type (2021-2026)
- 2.3.2 Europe Biosimilar Therapeutic Peptides Market Size Breakdown by Type (2021-2026)
- 2.3.3 Asia-Pacific Biosimilar Therapeutic Peptides Market Size Breakdown by Type (2021-2026)
- 2.3.4 South America Biosimilar Therapeutic Peptides Market Size Breakdown by Type (2021-2026)
- 2.3.5 Middle East and Africa Biosimilar Therapeutic Peptides Market Size Breakdown by Type (2021-2026)
3 Biosimilar Therapeutic Peptides Market by Application
- 3.1 Type Introduction
- 3.1.1 Cancer
- 3.1.2 Metabolic Disorders
- 3.1.3 Dermatology
- 3.1.4 Gastrointestinal Disorders
- 3.1.5 Cardiovascular
- 3.1.6 Central Nervous Systems
- 3.1.7 Others
- 3.2 Global Biosimilar Therapeutic Peptides Market Size by Application
- 3.2.1 Global Biosimilar Therapeutic Peptides Market Size Overview by Application (2021-2032)
- 3.2.2 Global Biosimilar Therapeutic Peptides Historic Market Size Review by Application (2021-2026)
- 3.2.3 Global Biosimilar Therapeutic Peptides Market Size Forecasted by Application (2027-2032)
- 3.3 Global Biosimilar Therapeutic Peptides Market Size by Regions
- 3.3.1 North America Biosimilar Therapeutic Peptides Market Size Breakdown by Application (2021-2026)
- 3.3.2 Europe Biosimilar Therapeutic Peptides Market Size Breakdown by Application (2021-2026)
- 3.3.3 Asia-Pacific Biosimilar Therapeutic Peptides Market Size Breakdown by Application (2021-2026)
- 3.3.4 South America Biosimilar Therapeutic Peptides Market Size Breakdown by Application (2021-2026)
- 3.3.5 Middle East and Africa Biosimilar Therapeutic Peptides Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
- 4.1 Biosimilar Therapeutic Peptides Industry Trends
- 4.2 Biosimilar Therapeutic Peptides Industry Drivers
- 4.3 Biosimilar Therapeutic Peptides Industry Opportunities and Challenges
- 4.4 Biosimilar Therapeutic Peptides Industry Restraints
5 Competitive Insights by Company
- 5.1 Global Top Players by Biosimilar Therapeutic Peptides Revenue (2021-2026)
- 5.2 Global Biosimilar Therapeutic Peptides Industry Company Ranking, 2024 VS 2025 VS 2026
- 5.3 Global Biosimilar Therapeutic Peptides Key Company Headquarters & Area Served
- 5.4 Global Biosimilar Therapeutic Peptides Company, Product Type & Application
- 5.5 Global Biosimilar Therapeutic Peptides Company Commercialization Time
- 5.6 Market Competitive Analysis
- 5.6.1 Global Biosimilar Therapeutic Peptides Market CR5 and HHI
- 5.6.2 Global Top 5 and 10 Biosimilar Therapeutic Peptides Players Market Share by Revenue in 2025
- 5.6.3 2025 Biosimilar Therapeutic Peptides Tier 1, Tier 2, and Tier 3
6 Company Profiles
- 6.1 Takeda Pharmaceuticals
- 6.1.1 Takeda Pharmaceuticals Company Information
- 6.1.2 Takeda Pharmaceuticals Business Overview
- 6.1.3 Takeda Pharmaceuticals Biosimilar Therapeutic Peptides Revenue, Global Share and Gross Margin (2021-2026)
- 6.1.4 Takeda Pharmaceuticals Biosimilar Therapeutic Peptides Product Portfolio
- 6.1.5 Takeda Pharmaceuticals Recent Developments
- 6.2 Sanofi
- 6.2.1 Sanofi Company Information
- 6.2.2 Sanofi Business Overview
- 6.2.3 Sanofi Biosimilar Therapeutic Peptides Revenue, Global Share and Gross Margin (2021-2026)
- 6.2.4 Sanofi Biosimilar Therapeutic Peptides Product Portfolio
- 6.2.5 Sanofi Recent Developments
- 6.3 Novartis AG
- 6.3.1 Novartis AG Company Information
- 6.3.2 Novartis AG Business Overview
- 6.3.3 Novartis AG Biosimilar Therapeutic Peptides Revenue, Global Share and Gross Margin (2021-2026)
- 6.3.4 Novartis AG Biosimilar Therapeutic Peptides Product Portfolio
- 6.3.5 Novartis AG Recent Developments
- 6.4 li Lilly and Company
- 6.4.1 li Lilly and Company Company Information
- 6.4.2 li Lilly and Company Business Overview
- 6.4.3 li Lilly and Company Biosimilar Therapeutic Peptides Revenue, Global Share and Gross Margin (2021-2026)
- 6.4.4 li Lilly and Company Biosimilar Therapeutic Peptides Product Portfolio
- 6.4.5 li Lilly and Company Recent Developments
- 6.5 Pfizer
- 6.5.1 Pfizer Company Information
- 6.5.2 Pfizer Business Overview
- 6.5.3 Pfizer Biosimilar Therapeutic Peptides Revenue, Global Share and Gross Margin (2021-2026)
- 6.5.4 Pfizer Biosimilar Therapeutic Peptides Product Portfolio
- 6.5.5 Pfizer Recent Developments
- 6.6 GlaxoSmithKline
- 6.6.1 GlaxoSmithKline Company Information
- 6.6.2 GlaxoSmithKline Business Overview
- 6.6.3 GlaxoSmithKline Biosimilar Therapeutic Peptides Revenue, Global Share and Gross Margin (2021-2026)
- 6.6.4 GlaxoSmithKline Biosimilar Therapeutic Peptides Product Portfolio
- 6.6.5 GlaxoSmithKline Recent Developments
- 6.7 Amgen
- 6.7.1 Amgen Company Information
- 6.7.2 Amgen Business Overview
- 6.7.3 Amgen Biosimilar Therapeutic Peptides Revenue, Global Share and Gross Margin (2021-2026)
- 6.7.4 Amgen Biosimilar Therapeutic Peptides Product Portfolio
- 6.7.5 Amgen Recent Developments
- 6.8 AstraZeneca
- 6.8.1 AstraZeneca Company Information
- 6.8.2 AstraZeneca Business Overview
- 6.8.3 AstraZeneca Biosimilar Therapeutic Peptides Revenue, Global Share and Gross Margin (2021-2026)
- 6.8.4 AstraZeneca Biosimilar Therapeutic Peptides Product Portfolio
- 6.8.5 AstraZeneca Recent Developments
- 6.9 Teva Pharmaceuticals
- 6.9.1 Teva Pharmaceuticals Company Information
- 6.9.2 Teva Pharmaceuticals Business Overview
- 6.9.3 Teva Pharmaceuticals Biosimilar Therapeutic Peptides Revenue, Global Share and Gross Margin (2021-2026)
- 6.9.4 Teva Pharmaceuticals Biosimilar Therapeutic Peptides Product Portfolio
- 6.9.5 Teva Pharmaceuticals Recent Developments
- 6.10 Novo Nordisk
- 6.10.1 Novo Nordisk Company Information
- 6.10.2 Novo Nordisk Business Overview
- 6.10.3 Novo Nordisk Biosimilar Therapeutic Peptides Revenue, Global Share and Gross Margin (2021-2026)
- 6.10.4 Novo Nordisk Biosimilar Therapeutic Peptides Product Portfolio
- 6.10.5 Novo Nordisk Recent Developments
7 North America
- 7.1 North America Biosimilar Therapeutic Peptides Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 7.2 North America Biosimilar Therapeutic Peptides Market Size by Country (2021-2026)
- 7.3 North America Biosimilar Therapeutic Peptides Market Size Forecast by Country (2027-2032)
8 Europe
- 8.1 Europe Biosimilar Therapeutic Peptides Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 8.2 Europe Biosimilar Therapeutic Peptides Market Size by Country (2021-2026)
- 8.3 Europe Biosimilar Therapeutic Peptides Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
- 9.1 Asia-Pacific Biosimilar Therapeutic Peptides Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 9.2 Asia-Pacific Biosimilar Therapeutic Peptides Market Size by Country (2021-2026)
- 9.3 Asia-Pacific Biosimilar Therapeutic Peptides Market Size Forecast by Country (2027-2032)
10 South America
- 10.1 South America Biosimilar Therapeutic Peptides Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 10.2 South America Biosimilar Therapeutic Peptides Market Size by Country (2021-2026)
- 10.3 South America Biosimilar Therapeutic Peptides Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
- 11.1 Middle East & Africa Biosimilar Therapeutic Peptides Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 11.2 Middle East & Africa Biosimilar Therapeutic Peptides Market Size by Country (2021-2026)
- 11.3 Middle East & Africa Biosimilar Therapeutic Peptides Market Size Forecast by Country (2027-2032)
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst